Clinical Trial

Lactobacillus Reuteri Strain Combination in Children Treated With PPI

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Probiotics might be of help in preventing dysbiosis and emergence of SIBO. Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475; the first have extensive data supporting its use in gastric infections (18) however, it lacks the anti-inflammatory properties that have been provided by L. Reuteri DSM ATCC PTA 6475 that has excellent acid resistance and has strong anti-inflammatory properties (19); for these reasons, Gastrus is the best candidate for this indication.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-07-29.
Trial Details
NCT Number NCT05484128
Lead Sponsor University of Bari
Conditions Gastric Lesion, Proton Pump Inhibitor Adverse Reaction, Probiotic
Enrollment 172 participants
Start Date 2020-03-04
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-05